(Q36602762)

15 August 2017

1 reference

title

Basic principles of intravenous immunoglobulin (IVIg) treatment (English)

1 reference

15 August 2017

Martin Stangel

1

1 reference

PubMed ID

16998749

15 August 2017

Refik Pul

series ordinal

2

1 reference

15 August 2017

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

253 Suppl 5

1 reference

15 August 2017

V18-24

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-006-5003-1

15 August 2017

0 references

cites work

Clinical uses of intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5003-1

Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5003-1

Sustained remission of CIDP associated with Evans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5003-1

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5003-1

Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5003-1

Intravenöse Immunglobulinsubstitution bei Antikörpermangelsyndrom

21 January 2018

1 reference

12 December 2020

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

12 December 2020

IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment

1 reference

12 December 2020

[Indications for the use of immunoglobulin therapy]

1 reference

12 December 2020

Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg)

1 reference

12 December 2020

Treatment of Guillain-Barré syndrome with high-dose gammaglobulin

1 reference

12 December 2020

Intravenous immunoglobulin therapy for antibody deficiency

1 reference

12 December 2020

Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo

1 reference

12 December 2020

Changes in cerebral oxygen consumption are independent of changes in body oxygen consumption after severe head injury in childhood

1 reference

12 December 2020

Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway

1 reference

12 December 2020

Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)

1 reference

12 December 2020

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

12 December 2020

Undegraded human immunoglobulin for intravenous use

1 reference

12 December 2020

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

1 reference

12 December 2020

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

12 December 2020

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

12 December 2020

F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

1 reference

12 December 2020

Humoral autoimmunity as a mediator of CNS repair

1 reference

12 December 2020

1 reference

12 December 2020

Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

1 reference

12 December 2020

Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]

1 reference

12 December 2020

Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

1 reference

12 December 2020

[On new possibilities of intravenous gamma globulin administration.]

1 reference

12 December 2020

NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease

1 reference

12 December 2020

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients

1 reference

12 December 2020

Treatment of dys-immune neuropathies.

1 reference

12 December 2020

Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations

1 reference

12 December 2020

In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens

1 reference

12 December 2020

In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins

1 reference

12 December 2020

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

12 December 2020

Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation.

1 reference

12 December 2020

Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes

1 reference

12 December 2020

Manipulating the Immune System with Immune Globulin

1 reference

12 December 2020

Antibody-mediated remyelination operates through mechanism independent of immunomodulation

1 reference

12 December 2020

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

1 reference

12 December 2020

Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes.

1 reference

12 December 2020

Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes

1 reference

12 December 2020

[Therapy of multiple sclerosis with immunoglobulin G]

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

Intravenous administration of human gamma-globulin

1 reference

12 December 2020

Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain

1 reference

12 December 2020

[A clinical model for regulation of the humoral immune response]

1 reference

12 December 2020

Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig

1 reference

12 December 2020

Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties

1 reference

12 December 2020

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

1 reference

12 December 2020

[Use of i.v. immunoglobulins in neurology. Evidence-based consensus]

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes

1 reference

12 December 2020

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

12 December 2020

Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

12 December 2020

Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

1 reference

12 December 2020

Structure and biological properties of immunoglobulins and gamma-globulin preparations. II. Properties of gamma-globulin preparations

1 reference

12 December 2020

Clinical results with a new intravenous immunoglobulin preparation (author's transl)

1 reference

12 December 2020

Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro

1 reference

12 December 2020

Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells

1 reference

12 December 2020

Normal polyclonal immunoglobulins ('IVIg') inhibit microglial phagocytosis in vitro

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination

1 reference

12 December 2020

Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages

1 reference

12 December 2020

10.1007/S00415-006-5003-1

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16998749